Thus, based on the available clinical evidence, the American Diabetes Association (ADA) [100] recommended GLP-1 RAs with demonstrated cardiovascular disease benefit as part of a comprehensive cardiorenal risk-reduction strategy for patients with T2DM. This evidence concerns the gene GCG and cardiovascular disorder.